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Abstract
Interferon regulatory factor 7 (IRF-7) was cloned within the 
biological context of Epstein–Barr virus (EBV) latency, and 
has an intimate relation with EBV. EBV latent membrane pro-
tein 1 (LMP-1) regulates IRF-7 both by inducing the expres-
sion of IRF-7 and by activating IRF-7 protein through phos-
phorylation and nuclear translocation in a post-translational 
manner. The activated IRF-7 then functions to regulate both 
EBV and cellular target genes involved in latency, transforma-
tion and immune regulation. IRF-7 appears to be a key cellu-
lar latency protein involved in both the pathogenesis and per-
sistence of EBV infection. 
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Introduction
Epstein–Barr virus (EBV) is a human herpes virus of 
increasing medical importance. EBV infection has been 
associated with the development of nasopharyngeal car-
cinoma (NPC) and Burkitt’s lymphoma (BL). In addition, 
EBV infection is an important cause of lymphomas in se-
verely immunocompromised people, especially patients 
with AIDS and organ-transplant recipients. EBV infection 
can significantly affect cell growth, differentiation and 
death by regulating complex genetic regulatory networks. 
Mounting evidence indicates that EBV can usurp cellu-
lar molecules for its own functions and persistence in the 
host in adaptations obviously acquired through evolution 
of virus–host interactions.1,2
Historically, interferon regulatory factor (IRF) was 
named after the cloning of IRF-1, which was implicated 
as a regulator of an interferon (IFN) gene at that time.3 
Currently, the IRF family has a total of nine members 
with multiple functions.4,5 The hallmark of this family is 
its N-terminal DNA-binding domain (DBD), which has 
five well-spaced, conserved tryptophan repeat sequences. 
The tryptophan repeat region can form a helix-turn-helix 
motif that latches onto DNA.6 Because of the conserved 
DBDs, IRFs can bind to consensus or similar DNA se-
quences with different names: interferon stimulated re-
sponse element (ISRE), positive regulatory element 
(PDE), and interferon consensus sequence (ICS), all of 
which have conserved GAAA repeats.7–11 The C-terminal 
region of IRFs is variable and defines multiple biologic 
functions including regulation of cell cycle, oncogenesis, 
apoptosis, and immune responses. In addition, IRF mem-
bers interact with one another and with other transcrip-
tion factors, such as Stats and PU.1, and as a consequence 
greatly expand the effects of IRFs.4,5
IRF-7 was cloned and identified within the biological 
context of EBV latency, based on its binding activity to 
the BamHI Q promoter (Qp) used in latent EBV infection 
for transcription of EBNA-1.12 The cDNA library selected 
for cloning IRF-7 was constructed from EBV-transformed 
human B lymphocytes, in which expression of IRF-7 was 
later found to be high.12,13 Serendipity thus led to the dis-
covery of IRF-7 and helped in its cloning. Although a low 
level of expression has been detected in all tissues exam-
ined, IRF-7 is a lymphoid-specific factor that is predomi-
nantly expressed in the spleen, thymus, and primary blood 
lymphocytes (PBL). Tissue-specific splicing is apparent: 
there are two major forms (2.0 and 2.6 kb) in spleen and 
thymus, and only one (2.0 kb) in PBL.12 Multiple splicing 
variants of IRF-7 have been identified, which are named 
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IRF-7A, 7B, 7C, and 7H.12,14 At least in PBL, IRF-7A ap-
pears to be the major protein form. As expected, IRF-7 
binds to ISRE as well as PDE,12,14,15 and the DBD is lo-
calized in the N-terminal region of the protein.12 Through 
random selection, the consensus sequence for IRF-7 bind-
ing sites was identified: 5′ GAAA/TNC/TGAAANT/C-
3′.16 The C-terminal region of IRF-7 contains the activa-
tion and regulation domain (ARD) (Figure 1); multiple 
subdomains in the region have been proposed.14,17
The effects of IRF-7 are not limited to EBV. Since 
IRF-7 was cloned, extensive work has been done in both 
EBV latency and in virally induced IFN systems to define 
the biological functions of IRF-7. A number of papers in-
dicate that IRF-7 plays a pivotal role in the induction of 
IFN genes after viral infections.14,15,17–19 The biologi-
cal functions and regulation of IRF-7 in EBV latency are 
still to be worked out. In this paper, we will focus mainly 
on two aspects of IRF-7 related to EBV latency: (1) how 
EBV regulates IRF-7; and (2) how IRF-7 regulates target 
genes involved in EBV latency, transformation and im-
mune regulation. 
Regulation of IRF-7 in EBV latent infection states
LMP-1 induces the expression of IRF-7
The biologic hallmark of the EBV–cell interaction is 
latency. Several types of latency have been described, 
each having its own distinct pattern of gene expres-
sion. In type I latency, EBV nuclear antigen 1 (EBNA-
1) is the major, and possibly the only, viral protein ex-
pressed. However, in type III latency, nine viral proteins 
are expressed, including latent membrane protein 1 
(LMP-1).1,2
LMP-1 is an integral membrane protein that is ex-
pressed during EBV latency. LMP-1 acts as a constitu-
tively active receptor-like molecule that does not need 
the binding of a ligand.2,20 LMP-1 has six transmem-
brane-spanning domains with a long C-terminal domain, 
which is located in the cytoplasm.21 The transmembrane 
domains mediate oligomerization of LMP-1 molecules 
in the plasma membrane, a prerequisite for LMP-1 func-
tions.20,22 LMP-1 can activate many important cellular 
signaling molecules including tumor necrosis factor re-
ceptor (TNFR)-associated factors (TRAFs), TNFR-asso-
ciated death domain protein (TRADD), nuclear factor κB 
(NFκB), c-Jun N-terminal kinase (JNK), janus kinase 3 
(JAK3) as well as signal transducer and activator of tran-
scription 1 (STAT 1).2 Through activation of these cellu-
lar molecules, LMP-1 is emerging as a central effector of 
altered cell growth and survival in EBV immortalization 
and transformation processes, as well as the effector of 
the adhesive and invasive potential of EBV-transformed 
cells.23–28
The intimate relation between IRF-7 and EBV latency 
was first noticed after the initial cloning. IRF-7 protein is 
expressed at high levels in EBV type III latency, in which 
LMP-1 is expressed; however, IRF-7 is barely expressed 
in type I latency, in which LMP- 1 is not expressed. This 
result suggested that one or more viral proteins expressed 
in type III latency might be responsible for the induction 
of IRF-7. In order to narrow down the potential respon-
sible gene(s), cells infected with EBV P3HR-1 or B95-
8 strains were used to examine the expression of IRF-7.29 
One difference between the P3HR1 and B95-8 strains is 
that cells infected with the B95-8 strain express high lev-
els of LMP-1. In contrast cells infected with P3HR1 vi-
rus express very low levels of LMP-1 and low levels of 
IRF-7.28,30 High levels of IRF-7 are associated with LMP-
1 expression in B95-8-infected cell lines.30 Furthermore, 
stable expression of LMP-1 in EBV-negative B cells in-
creased the expression of endogenous IRF-7. Also, tran-
sient transfection of LMP-1 into B cells could induce the 
expression of endogenous IRF-7.30 All these data suggest 
that LMP-1 is a necessary factor for the stimulation of the 
expression of IRF-7 in EBV-infected cells. 
The mechanism for the induction of IRF-7 RNA by 
LMP-1 is partially elucidated. LMP-1 is a membrane pro-
tein and depends heavily, if not exclusively, on cellular 
Figure 1. Structure of IRF-7 protein. ORFs are represented by 
open and solid bars. IRF-7B is missing 29 amino acids in the 
middle. IRF-7C has a 13-amino acid sequence difference from 
IRF-7A in its C-terminus, indicated by the solid bar. IRF-7H 
differs from IRF-7A by 18 amino acids at the very N-termi-
nal region indicated by the gray bar. DBD and ARD are also 
indicated. 
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signaling molecules for its function. Generally, two re-
gions in the C-terminus of LMP-1 have been shown to 
initiate signaling processes, the C-terminal activator re-
gions 1 (CTAR-1) and 2 (CTAR-2). Our results provide 
strong evidence that the two regions of LMP-1 can inde-
pendently induce the expression of IRF-7. The important 
implication of this result is that IRF-7 may be an essen-
tial factor for EBV latency, and LMP-1 may need to use 
two independent pathways, regardless of different cellular 
environments, to ensure the induction of IRF-7. Specifi-
cally, TRAFs and NFκB are involved in the induction of 
IRF-7 expression.31
LMP-1 activates IRF-7 protein in a post-translational 
manner
In addition to induction of the expression of IRF-
7, LMP-1 can also regulate IRF-7 protein activity post-
translationally. Originally, we found that both IRF-7 and 
LMP-1 are required for the activation of endogenous cel-
lular transporter associated with antigen processing 2 
(Tap-2).32 To understand the apparent synergy between 
LMP-1 and IRF-7, we tested the ability of LMP-1 to reg-
ulate IRF-7 by phosphorylation and nuclear transloca-
tion because post-translational modification of IRF-7 had 
been reported.14,15 Also, regulation of cellular genes by 
phosphorylation and nuclear translocation is not without 
precedent for LMP-1. It is well established that LMP-1 
phosphorylates IκB and translocates NF-κB from the cy-
toplasm to the nucleus.1,2
Interestingly, IRF-7 itself is a phosphoprotein. How-
ever, the expression of LMP-1 augments the phosphor-
ylation status of IRF-7. Furthermore, IRF-7 itself is pre-
dominantly a cytoplasmic protein, and the expression of 
LMP-1 facilitates its movement to the nucleus.32 These re-
sults suggest that endogenous IRF-7 is constitutively acti-
vated in EBV latency where both IRF-7 and LMP-1 are 
expressed. As expected, IRF-7 in EBV type III latency is 
indeed constitutively active as judged by phosphorylation 
status and nuclear localization.32
The mechanism for the post-translational activation of 
IRF-7 protein by LMP-1 is completely unknown. Other 
than EBV LMP-1, other agents such as viral infection 
(e.g. Sendai virus) and DNA damaging agents (e.g. UV 
light) can activate IRF-7 protein by phosphorylation and 
nuclear translocation.14,15,17,33 It seems likely that the ac-
tivation of IRF-7 protein by phosphorylation and nuclear 
translocation is a common theme for the regulation of 
IRF-7 activity. 
IRF-7 regulates EBV latency
Regulation of an EBV latency promoter by IRF-7
EBNA-1 is the sole viral protein needed for the repli-
cation of the EBV episome and maintenance of the latent 
infection state; both events are essential for viral persis-
tence and cell transformation. Qp is used for the transcrip-
tion of EBNA-1 mRNA in type I latency; however, Qp is 
silent in type III latency, and another promoter (C/Wp) is 
used for EBNA-1.1,2
The functional importance of Qp in the EBV life cycle 
is underscored by the following facts: (1) Qp usage is not 
only related to EBV persistence in an immunocompetent 
host, but it is also associated with several EBV-positive 
tumors; (2) all EBV-positive tumor specimens collected 
from Africa, North America, and Asia have conserved Qp 
sequence;34 and (3) conserved structural and functional 
cis-elements (e.g. ISRE and the Q-locus, Figure 3) also 
exist in the old world primate lymphocryptoviruses that 
are simian EBV-like viruses.35 Thus it is obvious that dis-
secting the regulation of Qp is essential for understanding 
the viral program in persistence and pathogenesis. Both 
EBNA-1 and host factors are involved in the transcrip-
tional regulation of Qp. EBNA-1 can bind to downstream 
elements of Qp, the Q locus, and acts in an autoregulatory 
manner to repress Qp transcription.36,37 However, E2F-1 
overcomes EBNA-1-mediated repression of Qp in tran-
sient transfection assays, and E2F-1 binds to the Q locus 
and displaces the binding of EBNA-1,38 so that the pro-
moter is regulated in a cell-cycle dependent manner with 
the peak level of EBNA-1 mRNA reached synchronously 
with S-phase.39
There is a body of evidence to support the role of IRF-
7 as a negative regulator of Qp. IRF-7 was cloned from 
its binding activity to Qp and subsequently proven to bind 
to Qp both in vitro with EMSA and in vivo with chromo-
somal immunoprecipitation (CHIP) assay as used in the 
analysis of IRF-7 binding to the Tap-2 promoter12,32 (also 
Zhang and Pagano, unpublished results). The expression 
of IRF-7 is high in EBV type III latency, where Qp is in-
active, and is low in EBV type I latency, where Qp is ac-
tive. Qp reactivation from type III latency by cell fusion 
is associated with a sharp reduction in expression of IRF-
7.40 IRF-7 represses the activity of Qp-reporter constructs 
in transient transfection assays. Finally, IFN-α, but not 
IFN-γ, is able to induce the expression of IRF-7,14,30,41 
and IFN-α, but not IFN-γ, represses endogenous Qp ac-
tivity in type I cells, as well as the activity of Qp-reporter 
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Figure 2. Model for the inactivation of Qp in type III latency. Schematic diagram of type I and type III latency cells and their 
Qp status is depicted. In type I latency, there is neither LMP-1 nor EBNA-2 expression, and only low level expression of IRF-
7, IRF-2, and EBNA-1. The putative activator(s) of Qp (Act) functions through ISRE and E2F functions through the Q locus to 
activate Qp. However in type III latency, EBNA-2 induces the expression of LMP-1, which in turn causes high expression of 
IRF-7. EBNA-2 also increases the expression of EBNA-1. How IRF-2 is up-regulated is currently unknown. The high levels of 
IRF-7, IRF-2 and EBNA-1 collectively inactivate Qp in type III latency by keeping the putative activator, as well as E2F, away 
from Qp. 
Figure 3. Schematic diagram of EBV–cell interactions underlying primary infection and persistence. First in acutely infected 
B cells, EBV expresses all the viral latency genes, including LMP-1, which in turn causes higher levels of expression of IRF-7, 
Tap-2, and HLA class I molecules. These cells proliferate transiently before the EBV-specific CTLs develop. Second, a life-long 
viral persistent state with no LMP-1 expression arises, which has selectively survived EBV-specific CTL attack; these cells es-
cape immune surveillance. A presumed latency switch generates the persistent state. 
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constructs in transient transfection assays.30 Thus, the data 
overwhelmingly support the idea that IRF-7 is a repressor 
of Qp, functioning to keep the promoter inactive in type 
III latency, where C/Wp is used instead. 
The fact that LMP-1 induces the expression of IRF-7 
predicts that LMP-1 may be able to repress Qp through 
IRF-7. Indeed, LMP-1 could repress the activity of Qp re-
porter constructs and the endogenous Qp. The repression 
of Qp is apparently associated with the ability to induce 
the expression of endogenous IRF-7. EBNA-2, which 
could not stimulate the expression of IRF-7, could not re-
press the activity of Qp reporter constructs. Nor did LMP-
1 repress Qp reporter and endogenous Qp in Akata cells 
in which IRF-7 could not be induced. Furthermore, mu-
tations in the ISRE of Qp abolish its repression by LMP-
1 or IRF-7. 30
It is apparent that Qp activity is a balanced outcome 
of positive and negative regulators, with IRFs strongly 
implicated in its regulation. In addition to IRF-7, IRF-2 
also negatively regulates Qp, and its expression is associ-
ated with EBV type III latency. 40 Thus in type III latency, 
Qp may be turned off by a combination of LMP-1, IRF-
7, IRF-2 and higher levels of EBNA-1. In contrast in type 
I latency, low levels or absence of these negative factors 
plus potential positive regulator(s) presumably cause the 
activation of Qp. The primary activator(s) of Qp is still 
unknown (Figure 2). Some evidence suggests that Stats 
play a role in the activation of Qp, but the identity of the 
Stat(s) is uncertain.42 The biological significance of Qp 
inactivation in type III latency is unclear. 
IRF-7 as a regulator of the host immune system
LMP-1 has been shown to regulate cellular immune 
genes including HLA 1, HLA II, Tap-1, and Tap-2.43,44 
We examined the genomic sequence available in Gene-
bank and found a putative ISRE sequence in the Tap-2 
promoter region. Because LMP-1 induces Tap-2 and IRF-
7, and IRF-7 has the potential to bind to Tap-2 ISRE, we 
reasoned that IRF-7 might be responsible for the induc-
tion of Tap-2 expression by LMP-1. The experimental re-
sults, summarized in the following, confirmed this hy-
pothesis. Endogenous Tap-2 expression correlates with 
both IRF-7 and LMP-1 expression in different cell lines. 
LMP-1 induces Tap-2 expression in B cells in which IRF-
7 can be induced. Also, ectopic expression of IRF-7 en-
hances the induction of Tap-2 by LMP-1. LMP-1 cannot 
induce Tap-2 in Akata Burkitt’s lymphoma cells, in which 
IRF-7 cannot be induced by LMP-1. However, the addi-
tion of IRF-7, which artificially restores the defect, acti-
vates the expression of Tap-2 in these cells. A Tap-2 pro-
moter construct could be activated by IRF-7, and further 
enhanced by LMP-1 specifically. Additionally, the acti-
vation of the Tap-2 promoter was dependent on an intact 
ISRE sequence. Finally, IRF-7 could bind specifically to 
the ISRE in the Tap-2 promoter in vitro and to endoge-
nous Tap-2 promoter sequence containing the ISRE in 
vivo under physiological conditions.32
In addition, it is apparent that IRF-7 is the most rel-
evant IRF member for the activation of Tap-2 by LMP-
1 for the following reasons. Expression of IRF-2 is also 
associated with EBV type III latency,40 where levels of 
Tap-2 are high. IRF-2 could also bind to the Tap-2 ISRE 
as determined by EMSA.32 However, IRF-2 cannot ac-
tivate the Tap-2 promoter reporter construct in at least 
two cell types. Nor could LMP-1 plus IRF-2 activate ei-
ther the Tap-2 promoter reporter construct or endoge-
nous Tap-2 in Akata cells in which IRF-7 is not inducible 
by LMP-1.32 Also, LMP-1 could not induce the expres-
sion of IRF-2 in several cell lines.30 Thus, IRF-2 appears 
not to be involved in the activation of Tap-2 by LMP-1. 
Next, LMP-1 could specifically enhance the activation of 
the Tap-2 promoter produced by IRF-7, but not by IRF-
1, although IRF-1 can activate the Tap-2 promoter con-
struct. Also, other IRFs tested, such as IRF-1, IRF-3, as 
well as ICSBP (IRF-8), are not associated with type III 
latency.30,40,41 Finally, LMP-1 facilitates the phosphory-
lation and nuclear translocation of IRF-7 for the activa-
tion of Tap-2.32
Since HLA 1, Tap-1 and Tap-2 are often induced si-
multaneously for antigen processing (e.g. by treatment 
with IFN-α, IFN-γ, or LPS), and they all have potential 
binding sequence for IRF, it is possible that IRF-7 may 
also be involved in the regulation of Tap-1 and HLA 1 
genes. Current data suggest that this notion may be cor-
rect, and that IRF-7 may regulate both Tap-1 and HLA 1 
in a fashion similar to Tap-2 (Zhang and Pagano, unpub-
lished results). IRF-7 may thus be a key protein involved 
in the regulation of the immune system. 
What advantage does EBV gain by inducing Tap-2 
and other HLA 1-related genes? An LMP-1-expressing 
EBV latency state (Type III) is established transiently 
in primary infection of human B cells in vivo.1,2 These 
LMP-1-expressing cells have enhanced growth, survival 
and invasive potential, which allow the EBV-infected 
cells to proliferate quickly, thereby putting the human 
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host at risk. This rapid proliferative process is checked 
by the appearance of EBV-specific primary cytotoxic T 
lymphocytes (CTL), which eliminate these type III la-
tency cells because of the activation of Tap-2 and other 
HLA 1-related genes by LMP-1 and IRF-7, and ensure 
the safety of the host. In X-linked immunoproliferative 
disease in which T cell activation is defective,45 EBV in-
fection is lethal. Interestingly, EBV in normal hosts still 
survives the CTL-attack by a transition to a type-I-like 
latency state, in which LMP-1 is not expressed. This 
type-I-like state, sometimes termed type 0 latency, can 
escape host immune surveillance, which ensures the sur-
vival of the virus.46–50 Because the whole process may 
ensure the survival both of the host and of the virus, a 
life-long coexistence may thus be maintained between 
the human host and EBV. In support of such a notion, 
the LMP-1-positive immunoblastic B cell lymphomas of 
the immunosuppressed are highly susceptible to restora-
tion of the patients’ T cell function or to adoptive CTL 
therapy.45,51–53 Thus, transient up-regulation of immune 
genes by IRF-7 and LMP-1 may set in motion selection 
of the persistent latently infected cells that do not ex-
press LMP-1 and eliminate these dangerous transforma-
tion-fated cells, resulting in survival of both the host and 
the virus (Figure 3). 
Other than facilitating such selection, the rapid ampli-
fication of type III latency cells would also increase the 
supply of cells available for the switch to persistent state 
(Figure 3). The type-I-like persistent EBV-positive cells, 
which are considered as memory B cell-like, usually do 
not replicate. The transient establishment of type III la-
tency may be the major contributor to and replenisher of 
the pool of persistently infected cells. 
IRF-7 as a putative oncogene
Of the many human viruses identified, only a few are 
so far considered oncogenic including EBV. The unique 
feature of EBV is its ability to immortalize and to trans-
form primary cells in vitro. LMP-1 is the principal on-
coprotein contributing to immortalization and transfor-
mation; during this process, EBV establishes latency 
concomitantly. In addition, LMP-1 is expressed in several 
EBV-associated tumors, such as NPC, AIDS-associated 
lymphoma, and post-transplantation lymphoproliferative 
disorders (PTLD).1,2
The linkage between IRFs and cancer was first sug-
gested by the finding that IRF-1 might be involved in 
oncogenesis as a tumor suppressor.54–56 Presently, sev-
eral lines of evidence indicate the involvement of IRFs 
in oncogenesis, and their potential role in human cancer 
has been suggested. Overexpression of IRF-2 or IRF-
4 causes oncogenic transformation in NIH 3T3 cells as 
well as in mice.56–58 Interestingly, some patients with 
multiple myeloma have a specific chromosomal translo-
cation resulting in overexpression of IRF-4. This translo-
cation is likely to be involved in the oncogenesis of this 
neoplasm.58 In addition, human herpes virus 8 (HHV-
8), also called Kaposi sarcoma associated herpes virus 
(KSHV), encodes several IRF-like molecules with par-
tial homology to cellular IRFs (vIRFs).59 At least vIRF-
1 causes oncogenic transformation in both cell lines and 
mice.60
With regards to IRF-7, available evidence suggests 
that IRF-7 may be oncogene-like and involved in the 
pathogenic processes triggered by EBV: first, expres-
sion and activation of IRF-7 protein are associated with 
the transformation state of EBV infection (type III la-
tency). Second, LMP-1, the principal oncogenic pro-
tein required for EBV transformation, regulates IRF-7 at 
both transcriptional and post-translational levels. Third, 
the LMP-1 signaling pathways that induce IRF-7 largely 
parallel those used by LMP-1 to transform cells. Fourth, 
TPA (phorbol ester), a carcinogen, induces the expres-
sion of IRF-7 (Zhang and Pagano, unpublished results). 
In addition to the circumstantial evidence, IRF-7 itself, 
in the absence of LMP-1 or TPA, causes focus forma-
tion as well as anchorage-independent growth in NIH 
3T3 cells (Zhang, Der, and Pagano, unpublished re-
sults). Thus, it seems likely that IRF-7 may be an on-
cogene and intimately involved in the pathogenesis of 
EBV-associated tumors. More work is needed to address 
this issue. 
Concluding remarks
Considering all the existing data, it is apparent that a 
novel signal transduction pathway has been discovered. 
That is, LMP-1 induces the expression of IRF-7, and fur-
ther activates IRF-7 protein by phosphorylation and nu-
clear translocation post-translationally. Finally, activated 
IRF-7 mediates the regulation of EBV target genes in-
volved in latency, immune regulation, and transformation 
(Figure 4). The interaction between LMP-1 and IRF-7 ap-
pears to be a triumph of natural selection and adaptation 
in viral evolution. 
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In addition to EBV, IRFs are likely to play important 
roles in other herpes viruses: infection by herpes simplex 
virus 1 (HSV-1) or human cytomegalovirus (HCMV) in-
duces the expression of IRF-7 (Zhang and Pagano, un-
published results). HCMV activates IRF-3 protein.61 
HHV-8 encodes four and rhesus rhadinovirus (RRV), en-
codes eight putative IRF homologues.59,62 The functions 
of these viral IRFs need to be identified. It is apparent 
that IRFs hold key information for virus–cell interactions, 
the understanding of which will be essential for efficient 
treatment and preventive measures against viral diseases. 
The function of IRF-7 has also been extensively studied 
in the activation of virally induced expression of IFNs. 
Viral infection can activate IRF-7 by phosphorylation and 
nuclear translocation that are required for the activation 
of a subset of IFN genes.14,15,17–19 Also, IRF-7 may be one 
of the common targets attacked by different viruses, e.g. 
vaccinia virus E3L, HHV-8 vIRF-3, and influenza virus 
NS1 genes are all able to block activation of IRF-7 pro-
tein.63,64 Thus, IRF-7 likely plays an important role in cel-
lular defense mechanisms against viruses. 
In summary, research on IRF-7 has entered a new 
stage. IRF-7 appears to be a multi-functional protein, and 
plays an essential role in EBV latency and transformation. 
EBV latency may prove to be an invaluable system to de-
cipher the biological roles of IRF-7 and serve as a model 
system for virus–IRF interaction. 
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